Clinical Trials Logo

Clinical Trial Summary

Patients expressing interest in participating will undergo psychiatric assessment to verify the diagnosis of treatment-resistant obsessive-compulsive disorder (OCD), assess symptom severity, and exclude TMS contraindications. The study involves a cycle of 35 continuous theta burst stimulations (cTBS) in the supplementary motor area (SMA) over 5 working days, with 7 stimulation sessions each day lasting 40 seconds. A 1-hour break between sessions will be observed, and each session will comprise 600 pulses at 90% of the motor threshold intensity. Biochemical analysis of blood serum from 40 patients will be conducted at three time points in an open-label study with active TMS stimulation: T0 - before starting stimulation T1 - after completing stimulation T2 - 1 month after completing stimulation Inclusion criteria: Diagnosis of depression or OCD according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) criteria, Hamilton Depression Rating Scale (HAM-D) score > 16 points, or Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score > 19 points; age 18-70 years. Exclusion criteria: Contraindications to TMS procedures, lack of informed consent, and documented persistent non-cooperation with treatment


Clinical Trial Description

Transcranial Magnetic Stimulation (TMS) is an accepted non-invasive method of neurostimulation. Evidence has demonstrated that TMS allows for the reduction of depression symptoms, and an increasing number of reports support its efficacy in reducing symptoms of obsessive-compulsive disorder (OCD). There is a limited body of clinical research available on the mechanisms of TMS action. Neuroplasticity refers to the capacity of neural tissue to form new connections for the purpose of reorganization and adaptation. Brain-Derived Neurotrophic Factor (BDNF) and Cell Adhesion Molecules (CAM) are markers of neuroplasticity. BDNF influences transmission in both excitatory and inhibitory synapses, enhancing neurotransmitter release in cholinergic and dopaminergic neurons. According to the neurotrophic hypothesis, stress may decrease BDNF levels. Serum BDNF concentrations are reduced in untreated patients with depression and normalized by antidepressant treatment. Neuronal CAMs are among the most prevalent proteins, playing a crucial role in synaptic plasticity. Various CAMs appear to interact with BDNF. In depression, both reduced BDNF levels and polysialylated (PSA) neuronal CAMs are observed. Conversely, the levels of Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intracellular Adhesion Molecule-1 (ICAM-1) in depression are inversely correlated with BDNF. To address this gap, the investiagators aimed to verify the hypothesis that TMS in OCD leads to symptom reduction by inducing neuroplasticity through: Comparing changes in BDNF and CAM protein concentrations after TMS stimulation in OCD patients before and after stimulation. Assessing the correlation between changes in BDNF and CAM concentrations and the reduction of psychopathological symptoms. Evaluating the predictive value of initial BDNF and CAM concentrations. Study assumptions and planned procedures: Patients expressing interest in participating will undergo psychiatric assessment to verify the diagnosis of treatment-resistant OCD, assess symptom severity, and exclude TMS contraindications. The study involves a cycle of 35 cTBS stimulations in the supplementary motor area (SMA) over 5 working days, with 7 TMS sessions each day lasting 40 seconds. A 1-hour break between sessions will be observed, and each session will comprise 600 pulses at 90% of the motor threshold intensity. Biochemical analysis of blood serum from 40 patients will be conducted at three time points in an open-label study with active TMS stimulation: T0 - before starting stimulation T1 - after completing stimulation T2 - 1 month after completing stimulation Inclusion criteria: Diagnosis of depression or OCD according to ICD-10 criteria, Hamilton Depression Rating Scale (HAM-D) score > 16 points, or Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score > 19 points; age 18-70 years. Exclusion criteria: Contraindications to TMS procedures, lack of informed consent, and documented persistent non-cooperation with treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06231095
Study type Interventional
Source Wroclaw Medical University
Contact
Status Completed
Phase Phase 4
Start date July 1, 2023
Completion date January 6, 2024

See also
  Status Clinical Trial Phase
Completed NCT00523718 - Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder Phase 2
Completed NCT00215137 - Pilot Study to Evaluate Escitalopram in Obsessive-compulsive Disorder Phase 2
Recruiting NCT06050369 - Objective Characterizatoion of Repetitive Behaviors N/A
Recruiting NCT06347978 - Personalized DBS for OCD Guided by Stereoencephalography Mapping N/A
Withdrawn NCT03926546 - Individual Versus Group Exposure With Response Prevention (ERP) for the Treatment of Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT05712057 - Neurostimulation Versus Therapy for Problems With Emotions N/A
Not yet recruiting NCT03313622 - Locating Biomarkers in OCD Through Behavioral Tasks
Withdrawn NCT03842345 - DELPhI Evaluation of Psychiatric Conditions
Completed NCT02866422 - Development of an Instrument That Monitors Behaviors Associated With OCD N/A
Completed NCT01833442 - Randomized Controlled Meditation Trial for Treating OCD N/A
Recruiting NCT04904952 - Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients N/A
Completed NCT05981690 - Therapist Guided, Parent-led, Cognitive Behavioural Therapy (CBT) for Preadolescent Children With Obsessive Compulsive Disorder (OCD) N/A
Recruiting NCT02500888 - Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder N/A
Recruiting NCT06244121 - Effect of Pyridoxine as Add-on Therapy in OCD Patients N/A
Recruiting NCT05580614 - Paired tVNS With ERP in OCD N/A
Active, not recruiting NCT03511534 - Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder N/A
Recruiting NCT05624528 - A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder Phase 2
Recruiting NCT05881356 - Discovering Factors in the Clinical Study Journey of Patients With OCD
Recruiting NCT05359562 - How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD N/A
Recruiting NCT03459456 - Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)